These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 36551540)

  • 1. Hypoxia-Inducible Factor-1: A Novel Therapeutic Target for the Management of Cancer, Drug Resistance, and Cancer-Related Pain.
    Bui BP; Nguyen PL; Lee K; Cho J
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds.
    Ma Z; Xiang X; Li S; Xie P; Gong Q; Goh BC; Wang L
    Semin Cancer Biol; 2022 May; 80():379-390. PubMed ID: 33002608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer.
    Yasuda H
    Nitric Oxide; 2008 Sep; 19(2):205-16. PubMed ID: 18503779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.
    Yu T; Tang B; Sun X
    Yonsei Med J; 2017 May; 58(3):489-496. PubMed ID: 28332352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation.
    Qannita RA; Alalami AI; Harb AA; Aleidi SM; Taneera J; Abu-Gharbieh E; El-Huneidi W; Saleh MA; Alzoubi KH; Semreen MH; Hudaib M; Bustanji Y
    Pharmaceuticals (Basel); 2024 Feb; 17(2):. PubMed ID: 38399410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy.
    Albadari N; Deng S; Li W
    Expert Opin Drug Discov; 2019 Jul; 14(7):667-682. PubMed ID: 31070059
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1alpha induction in response to hypoxic stress and growth factors.
    Chau NM; Rogers P; Aherne W; Carroll V; Collins I; McDonald E; Workman P; Ashcroft M
    Cancer Res; 2005 Jun; 65(11):4918-28. PubMed ID: 15930314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HIF-1α by Natural and Synthetic Compounds: A Promising Approach for Anti-Cancer Therapeutics Development.
    Ghosh R; Samanta P; Sarkar R; Biswas S; Saha P; Hajra S; Bhowmik A
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia-inducible factor-1 in human breast and prostate cancer.
    Kimbro KS; Simons JW
    Endocr Relat Cancer; 2006 Sep; 13(3):739-49. PubMed ID: 16954428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer therapeutic agents targeting hypoxia-inducible factor-1.
    Wang R; Zhou S; Li S
    Curr Med Chem; 2011; 18(21):3168-89. PubMed ID: 21671859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway.
    Rapisarda A; Uranchimeg B; Scudiero DA; Selby M; Sausville EA; Shoemaker RH; Melillo G
    Cancer Res; 2002 Aug; 62(15):4316-24. PubMed ID: 12154035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting HIF-2α in the Tumor Microenvironment: Redefining the Role of HIF-2α for Solid Cancer Therapy.
    Davis L; Recktenwald M; Hutt E; Fuller S; Briggs M; Goel A; Daringer N
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New anticancer strategies targeting HIF-1.
    Yeo EJ; Chun YS; Park JW
    Biochem Pharmacol; 2004 Sep; 68(6):1061-9. PubMed ID: 15313402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of DNA-dependent protein kinase with hypoxia inducible factor-1 and its implication in resistance to anticancer drugs in hypoxic tumor cells.
    Um JH; Kang CD; Bae JH; Shin GG; Kim DW; Kim DW; Chung BS; Kim SH
    Exp Mol Med; 2004 Jun; 36(3):233-42. PubMed ID: 15272235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-inducible factor-1 (HIF-1) inhibitors from the last decade (2007 to 2016): A "structure-activity relationship" perspective.
    Bhattarai D; Xu X; Lee K
    Med Res Rev; 2018 Jul; 38(4):1404-1442. PubMed ID: 29278273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-canonical approaches to targeting hypoxic tumors.
    Zhao S; El-Deiry WS
    Am J Cancer Res; 2022; 12(12):5351-5374. PubMed ID: 36628275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel thioredoxin inhibitors paradoxically increase hypoxia-inducible factor-alpha expression but decrease functional transcriptional activity, DNA binding, and degradation.
    Jones DT; Pugh CW; Wigfield S; Stevens MF; Harris AL
    Clin Cancer Res; 2006 Sep; 12(18):5384-94. PubMed ID: 17000671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress of hypoxia-inducible factor 1 inhibitors against tumors].
    Niu F; Li Y; Lai FF; Chen XG
    Yao Xue Xue Bao; 2014 Jun; 49(6):832-6. PubMed ID: 25212028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
    He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
    Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer.
    Ajith TA
    J Basic Clin Physiol Pharmacol; 2018 Dec; 30(1):11-18. PubMed ID: 30260792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.